Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers

Transplantation

Volumn 91, Issue 11, 2011, Pages 1279-1285

  Bertuzzo, Valentina Rosa ^a   Cescon, Matteo ^a,b   Ravaioli, Matteo ^a   Grazi, Gian Luca ^a   Ercolani, Giorgio ^a   Del Gaudio, Massimo ^a   Cucchetti, Alessandro ^a   D'Errico Grigioni, Antonietta ^a   Golfieri, Rita ^a   Pinna, Antonio Daniele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Inflammation markers; Liver transplantation; Microvascular invasion; Tumor recurrence

Indexed keywords

ALEMTUZUMAB; ALPHA FETOPROTEIN; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CHEMOEMBOLIZATION; CHILD; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FOLLOW UP; GRAFT REJECTION; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NEUTROPHIL TO LYMPHOCYTE RATIO; OVERALL SURVIVAL; PREDICTIVE VALUE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

ADOLESCENT; ADULT; AGED; ALPHA-FETOPROTEINS; C-REACTIVE PROTEIN; CARCINOMA, HEPATOCELLULAR; CHILD; FEMALE; HUMANS; INFLAMMATION; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPHILS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 79958296892     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182187cf0     Document Type: Article

References (61)

1. Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 1005.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907.
3. Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2005; 128: 1752.
4. Bismuth H, Chiche L, Adam R, et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993; 218: 145.
5. Ringe B, Pichlmayr R, Wittekind C, et al. Surgical treatment of hepatocellular carcinoma: Experience with liver resection and transplantation in 198 patients. World J Surg 1991; 15: 270.
6. Weimann A, Schlitt HJ, Oldhafer KJ, et al. Is liver transplantation superior to resection in early stage hepatocellular carcinoma? Transplant Proc 1999; 31: 500.
7. Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991; 214: 221.
8. Moreno P, Jaurrieta E, Figueras J, et al. Orthotopic liver transplantation: Treatment of choice in cirrhotic patients with hepatocellular carcinoma? Transplant Proc 1995; 27: 2296.
9. Van Thiel DH, Carr B, Iwatsuki S, et al. The 11-year Pittsburgh experience with liver transplantation for hepatocellular carcinoma: 1981-1991. J Surg Oncol Suppl 1993; 3: 78.
10. Ishizaki Y, Kawasaki S. The evolution of liver transplantation for hepatocellular carcinoma (past, present and future). J Gastroenterol 2008; 43: 18.
11. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693.
12. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394.
13. Takada Y, Ito T, Ueda M, et al. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: A proposal of expanded criteria. Dig Dis 2007; 25: 299.
14. Schwartz ME, D'Amico F, Vitale A, et al. Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid? Eur J Surg Oncol 2008; 34: 256.
15. Sotiropoulos GC, Malagó M, Molmenti E, et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: Is clinical tumor classification before transplantation realistic? Transplantation 2005; 79: 483.
16. Shah SA, Tan JC, McGilvray ID, et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 2006; 81: 1633.
17. Libbrecht L, Bielen D, Verslype C, et al. Focal lesions in cirrhotic explant livers: Pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002; 8: 749.
18. Varona MA, Del Pino JM, Barrera M, et al. Hepatocellular carcinoma and liver transplantation: A 12-year experience. Transplant Proc 2009; 41: 1005.
19. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 1080.
20. Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimetres. Ann Surg 2002; 235: 533.
21. Silva MA, Hegab B, Hyde C, et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: A systematic review and meta-analysis. Gut 2008; 57: 1592.
22. Van Der Poorten D, Kwok A, Lam T, et al. Twenty-year audit of percutaneous liver biopsy in a major Australian teaching hospital. Intern Med J 2006; 36: 692.
23. Shetty K, Timmins K, Brensinger C, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004; 10: 911.
24. Yamamoto K, Imamura H, Matsuyama Y, et al. Significance of alphafetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol 2009; 16: 2795.
25. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001; 357: 539.
26. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860.
27. Mantovani A, Allaven P, Sica A, et al. Cancer-related inflammation. Nature 2008; 454: 436.
28. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003; 90: 215.
29. Il'yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005; 14: 2413.
30. Erlinger TP, Platz EA, Rifai N, et al. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004; 291: 585.
31. Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005; 103: 1856.
32. Castell JV, Gomez-Lechon MJ, David M, et al. Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179.
33. Kawai Y, Matsuyama H, Korenaga Y, et al. Preoperative erythrocyte sedimentation rate is an independent prognostic factor in Japanese patients with localized clear cell renal cell carcinoma. Urol Int 2009; 83: 306.
34. Lehmann J, Retz M,Nürnberg N, et al. The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma. Cancer 2004; 101: 1552.
35. Forslund A, Engarås B, Lönnroth C, et al. Prediction of postoperative survival by preoperative serum concentrations of anti-p53 compared to CEA, CA 50, CA 242 and conventional blood tests in patients with colorectal carcinoma. Int J Oncol 2002; 20: 1013.
36. Bien E, Balcerska A. Serum soluble interleukin-2 receptor, beta2- microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma. Scand J Immunol 2009; 70: 490.
37. Walsh SR, Cook EJ, Goulder F, et al. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; 91: 181.
38. Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 2008; 34: 55.
39. Gomez D, Farid S, Malik HZ, et al. Preoperative neutrophil-tolymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 2008; 32: 1757.
40. Zahorec R. Ratio of neutrophil to lymphocyte counts-Rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001; 102: 5.
41. Halazun KJ, Hardy MA, Rana AA, et al. Negative impact of neutrophillymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009; 250: 141.
42. Ravaioli M, Grazi GL, Piscaglia F, et al. Liver transplantation for hepatocellular carcinoma: Results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008; 8: 2547.
43. Edmonson HA, Steiner PE. Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer 1954; 7: 462.
44. Vivarelli M, Dazzi A, Zanello M, et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010; 89: 227.
45. Toso C, Merani S, Bigam DL, et al. Sirolimus-based imunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237.
46. Chinnakotla S, Davis GL, Vasani S, et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009; 15: 1834.
47. Collins BH, Pirsch JD, Becker YT, et al. Long-term results of liver transplantation in older patients 60 years of age and older. Transplantation 2000; 70: 780.
48. Gaynor JJ, Moon JI, Kato T, et al. A cause-specific hazard rate analysis of prognostic factors among 877 adults who received primary orthotopic liver transplantation. Transplantation 2007; 84: 155.
49. Ravaioli M, Grazi GL, Dazzi A, et al. Survival benefit after liver transplantation: A single center experience. Transplantation 2009; 88: 826.
50. Porrett PM, Peterman H, Rosen M, et al. Lack of benefit of pretransplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl 2006; 12: 665.
51. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464.
52. Pawlik TM, Gleisner AL, Anders RA, et al. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: Implication for transplant eligibility. Ann Surg 2007; 245: 435.
53. Ravaioli M, Ercolani G, Cescon M, et al. Liver transplantation for hepatocellular carcinoma: Further considerations on selection criteria. Liver Transpl 2004; 10: 1195.
54. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitisCinfection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889.
55. Maluf DG, Edwards EB, Stravitz RT, et al. Impact of the donor risk index on the outcome of hepatitis C virus-positive liver transplant recipients. Liver Transpl 2009; 15: 592.
56. Bozorgzadeh A, Orloff M, Abt P, et al. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. Liver Transpl 2007; 13: 807.
57. Ravaioli M, Grazi GL, Ercolani G, et al. Partial necrosis of hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation 2004; 78: 1780.
58. Del Gaudio M, Ercolani G, Ravaioli M, et al. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transpl 2008; 8: 1177.
59. Zimmerman MA, Ghobrial M, Tong MJ, et al. Recurrence of hepatocellular carcinoma following liver transplantation: A review of preoperative and postoperative prognostic indicators. Arch Surg 2008; 143: 182; discussion 188.
60. Bruix J, Sherman M, Llovet JM, et al; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421.
61. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208.